Literature DB >> 25228650

High serum iron is associated with increased cancer risk.

Chi Pang Wen1, June Han Lee2, Ya-Ping Tai2, Christopher Wen3, Shiuan Be Wu2, Min Kuang Tsai2, Dennis P H Hsieh4, Hung-Che Chiang5, Chao Agnes Hsiung2, Chung Y Hsu6, Xifeng Wu7.   

Abstract

Epidemiologic studies linking high serum iron with cancer risks are limited and inconclusive, despite evidence implicating body iron in human carcinogenesis. A cohort of 309,443 adults in Taiwan who had no history of cancer had serum iron levels tested at the time of recruitment (1997-2008). Initially measured iron levels were associated with subsequent cancer risk by linking individuals with the National Cancer Registry and National Death File. HRs were calculated by the Cox model. One third of males (35%) and one fifth of females (18%) had high serum iron (≥120 μg/dL), which was associated with a 25% increase in risk for incidence of all cancers [HR, 1.25; 95% confidence interval (CI), 1.16-1.35] and with a 39% increase in risk for mortality from all cancers (HR, 1.39; 95% CI, 1.23-1.57). The relationship between serum iron and cancer risk was a J-shaped one, with higher cancer risk at both ends, either at lower than 60 μg/dL or higher than 120 μg/dL. At the higher end, cancer risk increased by 4% for every 10 μg/dL increment above 80 μg/dL, showing a dose-response relationship, with 60 to 79 μg/dL as a reference level. In a sensitivity analysis, the increases in risk were still observed after the first 5 years of cancer cases were excluded. Liver cancer risk was increased in HBV (-) non-hepatitis B carrier (3-fold) and HBV (+) hepatitis B carrier (24-fold). Lifestyle risks such as smoking, drinking, or inactivity interacted synergistically with high serum iron and significantly increased the cancer risks. The liver (HR, 2.49; 95% CI, 1.97-3.16) and the breast (HR, 1.31; 95% CI, 1.01-1.70) were the two major cancer sites where significant cancer risks were observed for serum iron either ≥120 μg/dL or ≥140 μg/dL, respectively. This study reveals that high serum iron is both a common disorder and a marker of increased risk for several cancers. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25228650     DOI: 10.1158/0008-5472.CAN-14-0360

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Serum Concentrations of 15 Elements Among Helicobacter Pylori-Infected Residents from Lujiang County with High Gastric Cancer Risk in Eastern China.

Authors:  Anla Hu; Li Li; Chuanlai Hu; Daoming Zhang; Chen Wang; Yan Jiang; Meng Zhang; Chunmei Liang; Wenjun Chen; Qingli Bo; Qihong Zhao
Journal:  Biol Trace Elem Res       Date:  2018-03-03       Impact factor: 3.738

2.  MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.

Authors:  L Zhang; Y Ye; H Tu; M A Hildebrandt; L Zhao; J V Heymach; J A Roth; X Wu
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

3.  ABO blood types and cancer risk--a cohort study of 339,432 subjects in Taiwan.

Authors:  Wenjie Sun; Chi-Pang Wen; Jie Lin; Christopher Wen; Xia Pu; Maosheng Huang; Min Kuang Tsai; Chwen Keng Tsao; Xifeng Wu; Wong-Ho Chow
Journal:  Cancer Epidemiol       Date:  2015-01-16       Impact factor: 2.984

4.  Detection of Ferritin Expression in Soft Tissue Sarcomas With MRI: Potential Implications for Iron Metabolic Therapy.

Authors:  Michael S Petronek; Ann M Tomanek-Chalkley; Varun Monga; Mohammed M Milhem; Benjamin J Miller; Vincent A Magnotta; Bryan G Allen
Journal:  Iowa Orthop J       Date:  2022-06

5.  Relationships between serum iron and liver diseases in nutrition intervention trials: A nested case-control study.

Authors:  Yiwei Liu; Jian Yin; Sanford M Dawsey; Bin Liu; Neal D Freedman; Jianfeng Cui; Philip R Taylor; Liangyu Yin; Christian C Abnet; Jinhu Fan; Wen Chen; Li Zhong; Youlin Qiao
Journal:  Cancer Epidemiol       Date:  2022-04-11       Impact factor: 2.890

6.  Metabolically programmed iron chelators.

Authors:  Raymond J Bergeron; Neelam Bharti; James S McManis; Jan Wiegand
Journal:  Bioorg Med Chem       Date:  2015-06-29       Impact factor: 3.641

7.  In vitro identification and characterisation of iron chelating catechol-containing natural products and derivatives.

Authors:  Gautam Rishi; V Nathan Subramaniam; Zachary J Hawula; Rohan A Davis; Daniel F Wallace
Journal:  Biometals       Date:  2021-04-28       Impact factor: 2.949

8.  Growth differentiation factor-15 and lactoferrin immuno-expression in breast cancer: relationship with body iron-status and survival outcome.

Authors:  Zheng Zhang; Hao-Jie Jiang; Huan-Huan Yang; Jin-Jin Ren; Guo-Qin Jiang; Jia-Ying Xu; Li-Qiang Qin
Journal:  Biometals       Date:  2021-01-23       Impact factor: 2.949

Review 9.  AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer.

Authors:  E Jensen-Jarolim; H J Bax; R Bianchini; S Crescioli; T R Daniels-Wells; D Dombrowicz; E Fiebiger; H J Gould; S Irshad; J Janda; D H Josephs; F Levi-Schaffer; L O'Mahony; G Pellizzari; M L Penichet; F Redegeld; F Roth-Walter; J Singer; E Untersmayr; L Vangelista; S N Karagiannis
Journal:  Allergy       Date:  2017-10-05       Impact factor: 13.146

10.  Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study.

Authors:  Cecilia Bosco; Wahyu Wulaningsih; Jennifer Melvin; Aida Santaolalla; Mario De Piano; Rhonda Arthur; Mieke Van Hemelrijck
Journal:  Ecancermedicalscience       Date:  2015-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.